NPTH.V - Biomed/telehealth stock trading below 1x revenues

NPTH is significantly undervalued compared to peers:
- 33M mkt cap with 50M revenue in 2019
- < 1 EV/sales vs 18.24x industry avg
- Recent 12M financing at .90
- Insider options at .87 + open market buys
- In major historical support zone
biomedFundamental AnalysisTechnical Indicatorstelehealth

Juga pada:

Penerbitan berkaitan

Penafian